HIV/AIDS

Featured Article
Examining the Correlation Between HIV Infection and Cognitive Impairment
Han-Zhu Qian, MD, PhD, MPH, explains the importance of screening cognitive functions and identifying the domains of cognitive impairment by age group among people living with HIV.
Review Finds High Lifetime Costs of Managing HIV
“Estimating the lifetime costs of managing HIV is useful for budgetary planning and to ensure HIV management is affordable for all,” the study concluded.
Utilizing Viral RNA Measurements in Patients With HIV
Jenn Zerbato, PhD, post-doctoral research fellow, Peter Doherty Institute for Infection and Immunity, breaks down why HIV RNA could serve as a better measure of efficient latency reversal in both pre…

Newsfeed

Examining the Correlation Between HIV Infection and Cognitive Impairment
Review Finds High Lifetime Costs of Managing HIV
Utilizing Viral RNA Measurements in Patients With HIV
Cost-Effective Treatment Option for Multidrug-Resistant HIV-1
Economic Evaluations of STI Control Programs Take Narrow Focus
Costs of HIV PrEP Could Curb Expansion, Researchers Warn
HIV/AIDS Costliest Chronic Condition Cluster in US Analysis
Addressing Barriers to Preventive HIV Care for At-Risk Patient Populations
View More

Insights

Examining the Correlation Between HIV Infection and Cognitive Impairment
Han-Zhu Qian, MD, PhD, MPH, explains the importance of screening cognitive functions and identifying the domains of cognitive impairment by age group among people living with HIV.
Utilizing Viral RNA Measurements in Patients With HIV
Jenn Zerbato, PhD, post-doctoral research fellow, Peter Doherty Institute for Infection and Immunity, breaks down why HIV RNA could serve as a better measure of efficient latency reversal in both pre-clinical and clinical assessment of latency…
Examining a New Class of Antiretroviral Therapy for Patients With Multidrug-Resistant HIV-1 Infection
Max Lataillade, DO, head of global research strategy, ViiV Healthcare, discusses the findings of the BRIGHTE study that demonstrated a significant decrease in HIV-1 RNA levels among patients treated with fostemsavir, a first-in-class investigational…
Addressing Treatment and Prevention of HIV
While great strides have been made in treating people with HIV over the past few decades, the US Preventive Task Force is strongly recommending PrEP for anyone at risk to help prevent the spread of the disease with which approximately 1.1 million…
View More

Interactive Features

Addressing Barriers to Preventive HIV Care for At-Risk Patient Populations
Ed Pezalla, MD, CEO, Enlightenment Bioconsult LLC, speaks about the barriers to preventive HIV care, pinpoints how payers can reach at-risk populations, and reviews the US Preventive Services Task Force’s measures requiring health plans to provide…
View More
Back to Top